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Objective: To evaluate the relation between obstructive 
sleep apnea (OSA) and left ventricular mass (LVM) in morbid 
obesity and the infl uence of gender, menopausal status, 
anthropometry, body composition, hypertension, and other 
cardiovascular risk factors in this relationship.
Design: Cross-sectional descriptive study.
Methods: Polysomnographic and echocardiographic 
studies were performed in a cohort of 242 patients (86 men, 
100 premenopausal (PreM) and 56 postmenopausal (PostM) 
women), with grade II obesity and above (BMI: 43.7 ± 0.4 kg/m2) 
to investigate OSA and LVM respectively. Anthropometry, 
body composition, glucose tolerance, and blood pressure 
were also recorded.
Results: OSA to different degrees was diagnosed in 76.2% of 
the patients (n: 166), its prevalence being 90.9% (n: 70) for men, 
and 76% (n: 38) and 63.8% (n: 58) for PostM and PreM women, 
respectively (p < 0.01). LVM excess was greatest for PostM 
women (90.2%), followed by men (81.9%) and PreM females 
(69.6%) (p < 0.01). LVM values increased in accordance to 
OSA severity (absence, 193.7 ± 6.9 g; mild, 192.6 ± 7.8 g; 
moderate, 240.5 ± 12.5 g; severe, 273.6 ± 14.6 g; p < 0.01). 
LVM magnitude correlated with the menopausal state, age, 
central adiposity, hypertension (HT), type 2 diabetes (DM), 
desaturation index (DI), and apnea-hypopnea index (AHI) 
(r = 0.41; p < 0.01). The relationship between LVM and AHI 
persisted in the multivariate analysis (β = 0.25; p < 0.05) 
after adjusting for age, gender, menopausal state, BMI, 
waist circumference, neck circumference, DI, fasting plasma 
glucose, DM, and HT. But if tobacco habits are included, the 
statistical difference disappears (β = 0.22; p = 0.06).
Conclusions: Morbid obesity is frequently associated 
with abnormal LVM, particularly in patients with OSA; this 
association is independent of HT, BMI, body composition, and 
other clinical factors, supporting a direct role of OSA on LVM 
in morbid obesity. This suggests that OSA and LVM might be 
taken as predictors of the cardiovascular risk in these patients.
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Obstructive sleep apnea (OSA) is characterized by intermit-tent and repeated occlusion of the upper airways during 
sleep, leading to partial (hypopnea) or total (apnea) interrup-
tions of the airfl ow.2 As a result, sustained variations in oxygen 
saturation and frequent wake up episodes take place, which may 
impair respiratory, cardiac, metabolic, and cognitive functions. 
OSA prevalence in the general population has been shown to 
be around 2% to 5% in women and 3% to 6% in men, although 
these values are probably underestimated due to diffi culties in 
confi rming the diagnosis and to the low relationship between 
the clinical manifestations and the number of apneas and 
hypopneas per hour (apnea-hypopnea index, AHI).2,3
Development of OSA depends on several factors such as 
age, menopause, alcohol consumption, smoking, and admin-
istration of drugs that induce muscle relaxation, thus favoring 
respiratory airfl ow obstruction.2,3 However, obesity may repre-
sent the most determining factor.2-4 In the context of the present 
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BRIEF SUMMARY
Current Knowledge/Study Rationale: This work was designed to ex-
plore the possible relationship between obstructive sleep apnea (OSA) 
and alterations of the left ventricular mass (LVM) in patients with morbid 
obesity. The infl uence of gender, menopausal status, body composition, 
and cardiovascular risk factors were also taken into consideration. The 
results show a high prevalence of sleep apnea and LVM alterations in 
this population, especially for men and PostM women. Interestingly, the 
apnea-hypopnea index related to LVM independently of age, gender, 
menopausal status, and other cardiovascular risk factors, including hy-
pertension. These results support a direct effect of OSA on LVM, and 
suggest that LVM should be assessed in all patients with morbid obesity 
and OSA, particularly men and postmenopausal women.
Study Impact: Morbid obesity is frequently associated to left ventricular 
mass alterations and obstructive sleep apnea. In this study we aimed to 
assess a possible direct relation between both cardiovascular risk fac-
tors and the infl uence played by complications such as hypertension and 
type 2 diabetes, often associated with obesity.
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obesity epidemic, the prevalence of subjects with BMI higher 
than 35 kg/m2 is increasing significantly, reaching 15.5% of the 
population in the USA.5 Obese patients frequently display an 
altered breathing pattern due, at least in part, to neck fat accu-
mulation, which provokes airway collapse during sleep. It is 
estimated that obesity multiplies the risk of OSA by ten, waist 
circumference being the anthropometric factor that best corre-
lates with its occurrence. This high OSA prevalence in morbidly 
obese patients contributes to increasing their cardiometabolic 
morbility by different mechanisms such as the increase of the 
extracellular volume and sodium retention, changes in the 
endothoracic pressure, and increase in sympathetic nervous 
system tone and renin angiotensin system activity.4 Further-
more, OSA is becoming a recognized cause of resistant hyper-
tension (HT),6,7 as deduced by the relation found between high 
AHI values and its development.8 The same may be true for 
the association between obesity and HT, which represent well-
established factors of left ventricular mass (LVM) increase 
and cardiovascular risk (CVR).9 But OSA might increase the 
risk of developing cardiovascular disease itself.7 It is known 
that OSA patients display alterations in myocardial function 
or structure.10,11 However, it is unclear whether these changes 
are due to OSA, obesity, or other frequently associated comor-
bidities, such as type 2 diabetes mellitus (DM) or HT. Given 
that an integral therapeutic approach should be programmed 
for most patients with OSA, it is important to know whether 
this condition is directly associated with myocardial distur-
bance, independent of the presence of other potentially related 
factors, such as fat mass excess, HT, or DM, since in that case 
the interest in detecting and treating OSA for cardiovascular 
prevention should be reinforced.
This study was designed to explore the relationship between 
OSA and the changes observed in LVM in morbidly obese 
patients, as well as to assess whether this relation is influenced 
by gender, age, menopausal state, body mass index (BMI), 
body composition, and HT.
METHODS
Patients
We examined 242 Spanish patients with morbid obesity, 
BMI ≥ 35 kg/m2 (BMI: 43.7 ± 0.4 kg/m2), of whom 156 were 
women (56 postmenopausal [PostM] and 100 premenopausal 
[PreM]) and 86 men. The mean age was 43.2 ± 0.8 years (range 
1,871 years). Patients with a history of coronary heart disease, 
heart failure, or established diagnosis of cardiac abnormali-
ties were excluded. They were recruited in the Endocrinology 
Department; the cause of consultation was obesity in all cases. 
The response rate was 88% (n = 215).
Anthropometry and Body Composition
All the patients were subjected to routine anthropometric 
examinations including body weight, height, and waist and 
neck circumference measurements. Body composition studies 
were carried out by air displacement plethysmography (Bod-
Pod; Life Measurements, Concord, CA, USA), which is a vali-
dated bicompartimental method to determine the percentage of 
fat mass and fat-free mass.12
Cardiovascular Risk Factors Studied
Smoking
Three groups were defined: non-smokers (those that never 
smoked), ex-smokers (who had given up smoking ≥ 6 months 
prior to the study), and active smokers.
Hypertension
Mean values of two measurements of blood pressure were 
considered. Patients undergoing antihypertensive treatment or 
those with systolic pressure > 140 mm Hg and/or diastolic pres-
sure > 90 mm Hg were considered as hypertensive.
Diabetes Mellitus
An oral glucose tolerance test (OGTT) was performed in 
all patients with no previous history of DM. The patients were 
diagnosed as diabetic if the syndrome had been diagnosed 
previously, were being treated, or the condition was shown by 
OGTT according to ADA criteria.
Biochemical Measurements
Fasting plasma glucose was measured by spectrometry using 
an enzymatic-colorimetric method. Fasting plasma insulin 
was determined by immunoassay (Immulite 2500. Siemens). 
As an indicator of insulin resistance, the HOMA index 
(insulin [μU / mL] × glucose [mmol] / 22.5) was calculated in 
all cases.
Polysomnographic Study
All patients underwent a full night polysomnographic study. 
Nocturnal sleep was recorded with a Harmonie 5.2 system 
(Stellate, Montreal, QC, Canada) using Lamont 32-Sleep 
amplifiers (Lamont Medical, Madison, WI, USA). The record-
ings included 7 electroencephalogram channels referenced to 
balanced mastoids, right and left electrooculogram, oxygen 
saturation, airflow thoracic-abdominal bands, body position 
sensor and electrocardiogram. In accordance with established 
criteria, apnea was defined as the cessation of nasal or oral 
airflow > 10 seconds. Hypopnea was defined as ≥ 30% decrease 
in the airflow channel > 10 sec, accompanied by ≥ 4% oxygen 
desaturation in ≥ 90% of the events.13 The AHI and DI were 
automatically calculated as functions of the mean number of 
apneic and hypopneic or desaturation events per hour of sleep, 
respectively. The frequency and severity of oxygen desatu-
rations were also measured. The hypnogram was visually 
analyzed off-line following standard criteria. The severity of 
OSA was classified according to the number of apnea events 
per hour following established criteria14: absent (< 5), mild 
(5-15), moderate (15-30), and severe (> 30).
Echocardiographic Study
Doppler echocardiography was carried out the day before the 
polysomnographic study. All determinations were performed 
by the same echocardiography specialist using a Sonos 
7500 (Philips, Eindhoven, The Netherlands). Morphological 
measurements were taken in M mode with respect to a para-
sternal long axis view.
The left ejection fraction was measured as a systolic func-
tion parameter (EF = (TDV − TSV) / TDV), where TDV and 
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TSV are the telediastolic and telesystolic volumes, respec-
tively. EF alterations were classified into 4 categories15: refer-
ence, ≥ 55%; mild alteration, 45% to 54%; moderate, 30% to 
44%; severe, < 30%.
The left ventricular mass (LVM) was calculated according 
to the formula: 0.8 {1.04 [(TDD + PPD + SD)3 – (TDD)3] + 
0.6 g}16, where TDD is the telediastolic diameter, PPD the 
diameter of the posterior wall and SD the septal diameter. 
The values were adjusted according to sex into the following 
categories of abnormality15: women: reference, 66-150 g; mild 
alteration, 151-171 g; moderate, 172-182 g; severe, > 183 g; 
men: reference, 96-200 g; mild alteration, 201-227 g; moderate, 
228-254 g; severe, > 255 g.
There is not a specific value adjusted for obesity, for this 
reason we adopted the most commonly used: LVM adjusted 
according to height (LVM/height2.7)17 and to the body surface 
[(BS (m2)]. In the first case a cutoff point of 51 g/m2 was taken 
as indicative of alteration,18,19 while in the second the formula 
height (cm) × weight (kg) / 3600 was used to calculate the 
left ventricular mass index (LVMI), defined as LVM/BS. As 
reference values 115 g/m2 in men and 95 g/m2 in women were 
taken.15 The geometry of the left ventricular mass of the patients 
was calculated as a function of their relative wall thickness 
(WRT, mm) and LVMI (g/m2) and classified into 4 groups15: 
normal: WRT ≤ 0.42 and LVMI ≤ 95 and ≤ 115 for women 
and men respectively; concentric remodelling: WRT > 0.42 and 
LVMI ≤ 95 (women) / ≤ 115 (men); concentric hypertrophy 
WRT > 0.42 and LVMI > 95 (women) / > 115 (men); eccen-
tric hypertrophy WRT ≤ 0.42 and LVMI > 95 (women) / > 115 
(men).
Informed consent was obtained from each patient after full 
explanation of the purpose and nature of all procedures used.
Statistical Analysis
The values are expressed as mean ± standard error for quan-
titative variables and as percentages for categorical variables. 
Means were compared for groups by one-way ANOVA with 
Bonferroni post hoc test and contingency tables to calculate χ2 
when comparing categorical variables. The correlation analyses 
were assessed with the Pearson correlation coefficient and with 
multivariate linear and logistic regression studies. All the anal-
yses were carried out with the statistical package SPSS v.15.0 
(SPSS, Inc., Chicago, IL).
RESULTS
General Characteristics of the Patients and Influence 
of Gender and Menopause
In Table 1 the information on the variables under study is 
recorded. It comprises the age of the patients, their anthropo-
metric characteristics, smoking habits, prevalence of HT and 
DM and the echocardiographic and polysomnographic data 
as a function of sex and menopausal state. The mean age was 
roughly equivalent between men and women and, as expected, 
PreM women were younger than their PostM counterpart. All 
patients displayed an obesity degree ≥ 2, and no significant 
differences were observed in their respective BMIs. The body 
composition analysis showed a higher percentage of fat mass 
in women (p < 0.01) with no differences between the PreM 
and PostM subgroups. Men presented a more intense central 
fat distribution than women, as deduced from their respective 
waist circumference measurements (p < 0.01). Similarly, neck 
circumference was higher in men than in women, being similar 
in the PreM and PostM clusters. No differences were observed 
in smoking habits. Hypertension was diagnosed in 55.4% of the 
patients, with men and PostM subgroups displaying a higher HT 
prevalence than PreM women. Diabetes was found in 25.6% 
of the patients, with no statistical difference between men and 
women as a whole; however, DM was significantly more prev-
alent in the PostM than in the PreM consortia. HOMA index 
calculations showed that men were more insulin resistant, with 
no differences between PreM and PostM women.
The prevalence of OSA in the whole group of patients was 
found to be 76.2%. However, the frequency among men rose up 
to 90.9%, while in women it accounted for 68.1%, the differ-
ence being statistically significant, as was that of the PreM 
(63.8%) and PostM (76%) clusters.
Similar echocardiographic values of the ejection frac-
tion were found for men and PreM and PostM women, all of 
them being within the normal range. Significant differences 
(p < 0.01) were found in the LVM values of men and women 
and, within the latter, between the PreM and PostM subgroups. 
However, when LVM was adjusted for height and body surface, 
the differences between women and men became less (p < 0.05) 
and nonsignificant, respectively, although they remained as 
such in the case of the PreM and PostM clusters. No difference 
was found in the WRT of the three cohorts under study. Finally, 
concentric and eccentric hypertrophies were similar for both 
sexes taken as a whole; nevertheless, the condition affected a 
significantly higher proportion of PostM than PreM women 
(p < 0.01).
Influence of Patient Characteristics on OSA 
Occurrence
In Table 2 the characteristics of the group of patients are 
related to the severity of OSA. A clear tendency towards its 
association with increasing age, weight, BMI, body fat, waist 
and neck circumference, and the HOMA index was observed 
(p < 0.01 in all cases). Similarly, the more severe the degree 
of OSA, the greater the likelihood of associated comorbidities, 
especially HT and DM. In contrast, the systolic function, as 
assessed by the LV ejection fraction, was similar irrespective of 
the degree of OSA severity.
A gradual increase in LVM was observed concomitant with 
OSA severity (p < 0.01) which was clearly enhanced by HT, as 
can be observed in Figure 1. Similarly, a gradual increment of 
LVM, when adjusted with respect to height, was seen as a func-
tion of the presence and intensity of OSA (p < 0.01). However, 
OSA severity did not correlate to heart hypertrophy or gender.
Univariate correlation of the data showed that LVM signifi-
cantly correlated with age (r = 0.24; p < 0.01), gender (r = 0.44; 
p < 0.01), menopausal state (r = 0.33; p < 0.01), BMI (r = 0.16; 
p < 0.01), percentage of fat mass (r = 0.21; p < 0.01), waist 
circumference (r = 0.42; p < 0.01), neck circumference (r = 0.44; 
p < 0.01), HT (r = 0.30; p < 0.01), DM (r = 0.35; p < 0.01), 
smoking habits (r = 0.15; p < 0.01), fasting plasma glucose 
(r = 0.19; p < 0.01), DI (r = 0.28; p < 0.01), and AHI (r = 0.41; 
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p < 0.01). No correlations were found with the HOMA index or 
with fasting plasma insulin.
The correlation between LVM and AHI persisted in the multi-
variate regression analysis (β = 0.25; p < 0.05) after adjusting 
for age, gender, menopausal state, BMI, waist circumference, 
neck circumference, DI, fasting plasma glucose, DM, and HT. 
But if tobacco habits are included the statistical difference 
disappears (β = 0.22; p = 0.06).
Similarly, the data on LVM adjusted for height were posi-
tively associated with age (r = 0.36; p < 0.01), gender (r = 0.16; 
p < 0.05), menopausal state (r = 0.34; p < 0.01), BMI (r = 0.18; 
p < 0.05), waist circumference (r = 0.29; p < 0.01), neck 
circumference (r = 0.19; p < 0.05), HT (r = 0.31; p < 0.01), 
DM (r = 0.41; p < 0.01), fasting plasma glucose (r = 0.21; 
p < 0.01) DI (r = 0.22; p < 0.01), and AHI (r = 0.41, p < 0.01). 
However, no relationship was found with the HOMA index, 
fasting plasma insulin, or fat mass. The correlation between 
LVM/height2.7 and AHI persisted in the multivariate regression 
analysis (β = 0.15; p < 0.05) after adjusting for age, gender, 
menopausal state, BMI, waist circumference, and HT.
Influence of Anthropometrical and Metabolic 
Parameters on the OSA–LVH Association
The univariate analysis of the left ventricular hypertrophy 
data with those on the severity of OSA indicates that a clear 
relation between them exists (Table 3). Since OSA is depen-
dent on several other factors, such as age, gender, menopausal 
state, and smoking habits, a multivariate analysis that took 
these variables into consideration was undertaken. The data 
obtained indicate that these factors significantly contributed to 
the outcome especially for patients that suffered moderate and 
severe OSA.
Table 1—Patient anthropometric characteristics, risk factors and echocardiographic study as a function of gender and menopausal 
state
Total
(n = 242)
Men
(n = 86)
Women
(n = 156) p
PreM women
(n = 100)
PostM women
(n = 56) p
Age (y) 43.2 ± 0.7 42.4 ± 1.1 43.6 ± 1.0 NS 36.2 ± 0.9 56.6 ± 0.7 **
Weight (kg) 120.7 ± 1.5 132.8 ± 2.3 113.9 ± 1.7 ** 116.5 ± 1.9 109.3 ± 3.1 *
BMI (kg/m2) 43.7 ± 0.4 43.4 ± 0.6 43.9 ± 0.5 NS 44.4 ± 0.7 43.0 ± 0.9 NS
Body fat (%) 49.9 ± 0.5 43.5 ± 0.7 53.2 ± 0.4 ** 53.1 ± 0.5 53.4 ± 0.7 NS
Neck circumference (cm) 41.3 ± 0.4 46.1 ± 0.7 39.1 ± 0.3 ** 38.7 ± 0.4 39.7 ± 0.6 NS
Waist circumference (cm) 122.7 ± 0.9 128.9 ± 1.3 119.3 ± 1.1 ** 118.3 ± 1.3 121.1 ± 1.9 NS
Tobacco (%)
Non-smoker
Ex-smoker
Smoker
57.9
10.3
31.8
51.2
10.5
38.4
61.5
10.3
28.2
NS
NS
NS
57.0
10.0
33.0
69.6
10.7
19.6
NS
NS
NS
HT (%) 55.4 67.4 48.7 ** 32.0 78.6 **
DM (%) 25.6 31.4 22.4 NS 14.0 37.5 **
HOMA 5.1 ± 0.2 5.9 ± 0.4 4.5 ± 0.3 ** 4.4 ± 0.3 4.8 ± 0.4 NS
OSA (%)
Absent
Mild
Moderate
Severe
23.8
27.1
20.2
28.9
9.1
16.9
18.2
55.8
31.9
32.6
21.3
14.2
**
**
**
**
36.2
37.4
12.1
14.3
24.0
24.0
38.0
14.0
**
**
**
**
EF (%) 59.9 ± 0.3 59.2 ± 0.6 60.4 ± 0.4 NS 60.4 ± 0.6 60.4 ± 0.8 NS
AHI 24.6 ± 1.8 41.1 ± 3.8 15.6 ± 1.6 ** 14.2 ± 2.0 18.1 ± 2.6 NS
DI 18.0 ± 1.8 28.1 ± 3.3 12.9 ± 2.0 ** 11.1 ± 2.6 16.0 ± 3,0 NS
LVM (g) 223.4 ± 5.7 275.2 ± 11.1 197.3 ± 5.4 ** 181.1 ± 5.7 226.3 ± 9.8 **
Altered LVM (%) 78.6 81.9 76.9 * 69.6 90.2 **
LVM/height2.7 (g/m2.7) 56.8 ± 1.3 61.4 ± 2.5 54.5 ± 1.5 * 49.8 ± 1.6 63.0 ± 2.8 *
AlteredLVM/height2.7(%) 49.2 53.5 46.8 NS 36.0 66.1 **
LVM/BS (g/m2) 98.9 ± 4.9 108.8 ± 4.3 93.9 ± 7.0 NS 79.5 ± 2.4 120.0 ± 18.7 **
Altered LVM/BS (g/m2) 40.9 % 41.9 % 40.4 % NS 27.0 % 64.3 % **
WRT (mm) 0.42 ± 0.01 0.42 ± 0.01 0.42 ± 0.01 NS 0.42 ± 0.01 0.42 ± 0.01 NS
Altered WRT (%) 47.1 48.8 46.2 NS 44.0 48.8 NS
Hypertrophy (%)
Eccentric
Concentric
20.7
20.2
22.1
19.8
19.9
20.5
NS
NS
14.0
13.0
30.4
33.9
**
**
NS, non-statistically significant difference; *p < 0.05; **p < 0.01.
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The inclusion of the BMI and fat mass data had a minor 
influence on the data recovered. Conversely, fat distribution 
played an important role, especially when neck perimeter was 
taken into consideration, thus confirming that blockage of 
the pulmonary airway is an important predisposing factor for 
OSA. Finally, while HT appeared to positively influence OSA 
severity, this relation was not noted with carbohydrate metabo-
lism alterations, such as DM.
DISCUSSION
The correlation between OSA and alteration of myocardial 
function is a controversial issue. While some studies have 
suggested a relation between LVH, AHI and the duration of 
oxygen saturation periods,20-22 research carried out on obese 
patients with or without OSA found no differences in their 
LVM.23 Furthermore, the association observed between the 
increase in LVM and OSA was not maintained after adjusting 
for BMI or other associated covariates, thus suggesting that 
other clinical factors might influence the link between OSA and 
the changes in myocardial morphology. However, the results of 
The Sleep Heart Health Study7 showed that increases in LVM 
Table 2—Comparison of the patient cohort anthropometric values, risk factors and echocardiographic data with their OSA severity
Absent Mild Moderate Severe p
Age (y) 39.4 ± 1.6 40.8 ± 1.7 47.8 ± 1.9 45.0 ± 1.2 **
Weight (kg) 112.5 ± 2.3 117.1 ± 2.4 119.1. ± 4.7 132.8 ± 2.8 **
BMI (kg/m2) 41.9 ± 0.7 43.5 ± 0.8 44.1 ± 1.1 45.6 ± 0.8 *
Body fat (%) 50.6 ± 1.0 50.9 ± 0.9 50.9 ± 1.1 47.7 ± 0.9 *
Neck circumference (cm) 38.6 ± 0.6 39.9 ± 0.5 42.5 ± 1.0 44.7 ± 0.9 **
Waist circumference (cm) 116.8 ± 1.5 118.7 ± 1.7 125.3 ± 2.2 130.3 ± 1.5 **
Tobacco (%)
Non-smoker
Ex-smoker
Smoker
57.7
7.7
34.6
64.4
10.2
25.4
63.6
4.5
31.8
42.9
15.9
41.3
NS
NS
NS
HT (%) 38.5 40.7 75.0 65.1 **
DM (%) 11.5 18.6 34.1 35.0 **
HOMA 3.7 ± 0.3 4.8 ± 0.5 5.6 ± 0.6 6.1 ± 0.5 **
EF (%) 59.7 ± 0.6 58.9 ± 0.7 60.5 ± 1.0 60.2 ± 0.7 NS
AHI 2.3 ± 0.2 8.6 ± 0.3 20.6 ± 0.6 60.8 ± 3.3 **
DI 3.4 ± 0.7 7.1 ± 1.8 14.8 ± 1.7 45.1 ± 4.7 **
LVM (g) 193.7 ± 6.9 192.6 ± 7.8 240.5 ± 12.2 273.6 ± 14.6 **
Altered LVM (%) 79.2 62.7 79.6 73.0 NS
LVM/height2.7 (g/m2.7) 51.6 ± 1.9 51.0 ± 2.0 62.6 ± 3.5 64.4 ± 3.1 **
Altered LVM/height2.7(%) 46.2 40.7 56.8 58.7 NS
LVM/BS (g/m2) 86.3 ± 2.8 83.6 ± 3.2 126.0 ± 23.8 108.8 ± 5.3 *
Altered LVM/BS (%) 38.5 32.2 43.2 47.6 NS
WRT (mm) 0.42 ± 0.01 0.41 ± 0.01 0.43 ± 0.01 0.43 ± 0.01 NS
Altered WRT (%) 46.2 40.7 54.4 52.4 NS
Hypertrophy (%)
Eccentric
Concentric
17.3
21.2
18.6
13.6
11.4
31.8
25.4
22.2
NS
NS
NS, non statistically significant difference; *p < 0.05; **p < 0.01.
Figure 1—LVM (g) evolution as a function of OSA severity in 
the absence and presence of HT
NS, non statistically significant difference; *p < 0.05.
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and in LVH prevalence were related to AHI, independent of 
age, sex, ethnicity, BMI, smoking, alcohol consumption, DM, 
and previous acute myocardial infarction.24
In the present study, we have addressed the relation of 
OSA severity with LVM increase in obese patients with BMIs 
over 35 kg/m2, to determine whether there was a cause/effect 
between both or if other cardiovascular risk factors, usually 
present in these patients, played a role as well. This might, in 
addition, promote the realization of prospective studies aiming 
to provide information on the possible effects of weight loss or 
gain on the OSA and LVM relationship.
The results obtained indicate that a high prevalence of OSA 
occurs in patients with morbid obesity, reaching 76.2% of the 
cases. A high prevalence of LVM alterations in morbidly obese 
patients that were affected by OSA (up to 78.6%) was observed, 
a result that agrees with that of a previous report where a 
sample of 25 obese patients (23 of which were males) was 
investigated.25 The frequency of LVM disturbance in women 
(68.1%) was significantly lower than in men, where only 9.1% 
of the individuals were free of the condition. The data obtained 
indicate that male-gender, a well-known predisposing factor for 
OSA in the general population, also influences its occurrence 
in obese patients. Nevertheless, obesity appears to increase the 
frequency of OSA in women as well, from about 50% found 
in the female population taken as a whole26 to the almost 70% 
found in our dataset. However, it appears that body fat distribu-
tion rather than excess total fat is responsible for the increased 
frequency of OSA in our patients; air displacement plethys-
mography indicated that men presented lower total fat figures 
than women but higher waist and neck circumferences, thus 
indicating that central fat deposition may be the real predis-
posing agent for OSA pathogenesis in morbidly obese patients.
The influence of the menopausal status of the obese patients 
on OSA was also clear; PostM women showed a significantly 
higher frequency (76.0%) than PreM women (63.8%). Similar 
data have previously been reported,27 although in that case 
larger neck circumference and higher waist to hip circumference 
ratios were found among PostM women and, as a consequence, 
were taken as predisposing factors for OSA (similar to what we 
have just discussed for men and women). However, our female 
cohorts presented similar anthropometric and body composition 
parameters, suggesting that other factors, such as age or/and 
hormonal status might also be responsible for OSA prevalence 
in the PostM subgroup. In agreement with this assumption, the 
administration of hormone replacement therapy to menopausal 
women was associated to a lower prevalence of OSA.28
As expected, our study revealed that morbid obesity is 
strongly associated with cardiovascular risk factors such as 
hypertension and DM2, which were more prevalent in men 
and PostM women and showed a significant correlation with 
obesity and central adiposity indexes such as BMI, waist, and 
neck circumference, and with AHI. However, it appears that 
there is a direct correlation between OSA severity and LVM 
increase, which may be independent of the other cardiovas-
cular risks. Furthermore, the changes in LVM were observed 
both in non- and hypertensive patients. However, HT induces 
more pronounced changes in the LVM of patients with OSA, 
suggesting a synergistic effect of both conditions. These data 
agree with those of recently published reports21,29 indicating 
that severe OSA impairs left ventricular function independent 
of age, insulin resistance or blood pressure,30 although these 
conditions may worsen it. LVH also represents an established 
cardiovascular risk factor31 particularly relevant in patients with 
severe OSA that exhibit an LVH prevalence of over 50% in our 
cohort. This relationship might be indirectly influenced by fat 
distribution, HT, and DM, all of which are conditions that prob-
ably influence the association between severe OSA and LVH.
It is known that insulin resistance promotes the increment 
of LVM and LVH through raising the extracellular volume and 
sodium retention32 and through hyperactivation of the renin-
aldosterone system.33 A direct relationship was found between 
HOMA and LVM alterations, which were independent of the 
age and other confounding factors such as HT.34 However, we 
could not find an association between fasting plasma insulin or 
HOMA index and LVM, suggesting that additional factors may 
be involved in the pathophysiology of LVM in patients with 
morbid obesity. On the other hand, the relation of fat distribu-
tion with both the degree of OSA severity and insulin resis-
tance suggests that the latter may be considered as an important 
anthropometric clue when OSA is suspected and therefore, 
may represent an indirect marker for detecting LVM alterations 
in obese patients.
Table 3—Cox proportional hazard ratios (95% CI) for the association between OSA and left ventricular hypertrophy
Absent Mild Moderate Severe
Cases 52 59 44 63
Univariate 1 0.76 (0.35-1.66) 1.22 (0.54-2.75) 1.45 (0.69-3.11)
Multivariate* 1 0.71 (0.31-1.63) 0.80 (0.32-1.96) 1.24 (0.52-3.00)
+ BMI 1 0.67 (0.29-1.60) 0.74 (0.29-1.83) 1.09 (0.44-2.70)
+ FAT% 1 0.58 (0.24-1.40) 0.72 (0.28-1.84) 0.95 (0.36-2.45)
+ circumference perimeter 1 0.62 (0.25-1.51) 0.68 (0.26-1.78) 0.83 (0.32-2.23)
+ neck perimeter 1 0.46 (0.15-1.43) 0.63 (0.18-2.45) 0.47 (0.12-1.84)
Multivariate* 1 0.71 (0.31-1.63) 0.80 (0.32-1.96) 1.24 (0.52-3.0)
+ HC alteration 1 0.77 (0.33-1.80) 0.82 (0.33-2.03) 1.23 (0.51-3.0)
+ HT 1 0.76 (0.32-1.83) 0.63 (0.25-1.62) 1.04 (0.41-2.60)
FAT%, percentage of fat mass; HC, carbohydrate metabolism; HT, hypertension. *Multivariate: model adjusted by age, gender, menopausal state, and 
smoking habits.
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In contrast with a previous report,24 our study showed no 
differences in the ejection fraction of patients included in any 
of the four categories of OSA severity, suggesting that OSA was 
not inducing changes in their systolic function. These discrep-
ancies may be due to the fact that patients with established 
cardiac disturbances were excluded from the previous report 
and to the age heterogeneity of our sample.
In summary, this study establishes that OSA is highly preva-
lent among morbidly obese patients, being especially frequent 
in men and PostM women. LVM alterations and LVH are also 
very common in these patients, and their occurrence is associ-
ated with OSA independent of other classic cardiovascular risk 
factors, including HT. These data suggest that OSA should be 
investigated and an echocardiographic study performed in all 
patients with morbid obesity, independent of their HT status, 
and especially in men and PostM women. The improvement 
obtained in myocardial performance following treatment with 
CPAP in patients with OSA,11 supports the interest of this diag-
nostic strategy in the prevention or treatment of myocardial 
dysfunction and cardiovascular risk in this group of patients.
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